Trial Profile
An Efficacy and Safety Trial of Intravitreal Injection of Conbercept Ophthalmic Injection in Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jul 2022
Price :
$35
*
At a glance
- Drugs Conbercept (Primary)
- Indications Retinal oedema
- Focus Therapeutic Use
- Acronyms CRAVE
- Sponsors Chengdu Kanghong Biotech
- 11 Jul 2022 Status changed from recruiting to completed.
- 19 Sep 2018 Planned End Date changed from 1 Oct 2018 to 1 Dec 2020.
- 19 Sep 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2019.